Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Advani on Advancements in the Treatment of TNBC

February 10th 2024

Pooja Advani, MBBS, MD, discusses key advancements that have occurred for the treatment of patients with triple-negative breast cancer.

The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer

February 9th 2024

The EMERALD study showed improved progression-free survival with elacestrant compared to standard endocrine therapy in patients with ESR1 mutations who progressed on prior AI and CDK4/6 inhibitors, with the greatest benefit in those having longer duration of response to first-line therapy.

CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer

February 9th 2024

Laura Huppert, MD, and Yara Abdou, MD, discuss the CAPItello-291 trial which looked at the efficacy of capivasertib, a small molecule AKT inhibitor, in combination with fulvestrant for patients with estrogen receptor positive, HER2 negative advanced breast cancer who had progressed on prior endocrine therapy.

Clinical Considerations of Genomic Testing in Early-Stage Breast Cancer

February 8th 2024

A discussion on clinical considerations for genomic testing in patients with early-stage breast cancer.

MammaPrint: A 70-Gene Signature Test for Patient with Breast Cancer

February 8th 2024

Dr. O’Shaughnessy introduces MammaPrint and BluePrint, discussing their role in genomic testing for patients with breast cancer.

Overview of Genomic Assays for Early-Stage Breast Cancer

February 8th 2024

A comprehensive overview of genomic assays conducted for patients with early-stage breast cancer including MammaPrint, BluePrint, Oncotype DX.

Goserelin Included in Latest NCCN Breast Cancer Guidelines

February 7th 2024

The NCCN Breast Cancer Panel has included goserelin at 2 dosing schedules as a method for ovarian function suppression in their updated guidelines.

Dr Meisel on Communication Barriers Between Patients and Oncologists in Breast Cancer

February 7th 2024

Jane L. Meisel, MD, discusses the rationale for evaluating communication challenges that currently exist between patients and their oncologists.

Ongoing Research and Unmet Needs in Patients With Breast Cancer and ESR1 Mutations

February 6th 2024

Drs Mayer and Kalinsky conclude their discussion with a look at agents in development and unmet needs for patients with breast cancer and ESR1 mutations.

HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

February 5th 2024

Erika Hamilton, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

World Cancer Day Highlights Ways to Address Gaps in Care for Black Patients With Breast Cancer

February 4th 2024

World Cancer Day is held every year on February 4th, prompting individuals across the globe to expand awareness within cancer care.

Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, review approaches to repeat hormone receptor and HER2 status testing before initiating later lines of therapy in patients with metastatic breast cancer.

The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, discuss data from the MAINTAIN trial on ribociclib in combination with endocrine therapy in patients with metastatic breast cancer.

Overview of the Treatment Landscape for HR+, HER2- Advanced or Metastatic Breast Cancer

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, provide an overview of the treatment landscape for HR+, HER2- advanced or metastatic breast cancer.

Dr McAndrew on the Implications of the PHERGain Study in HER2+ Breast Cancer

February 1st 2024

Nicholas P. McAndrew, MD, MSCE, discusses the implications of the phase 2 PHERGain study of chemotherapy de-escalation in patients with HER2-positive early breast cancer.

SERENA-2: Camizestrant vs Fulvestrant in Advanced ER+/HER2- Breast Cancer

January 30th 2024

Medical oncologists discuss oral SERDs, with a focus on the SERENA-2 trial looking at camizestrant in patients with advanced ER+/HER2- breast cancer.

The Role of Elacestrant in Breast Cancer

January 30th 2024

Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.

HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

January 25th 2024

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

EMERALD: Elacestrant in ER+/HER2- Advanced Breast Cancer

January 23rd 2024

Kevin Kalinsky, MD, MS, gives an overview of recent data from the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer.

PADA-1 Trial: ctDNA Monitoring for Acquired ESR1 Mutations in Advanced Breast Cancer

January 23rd 2024

Drs Mayer and Kalinsky provide insights and offer their impressions of the PADA-1 trial, focusing on ESR1 mutation monitoring with circulating tumor DNA (ctDNA).